Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 7/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059626 | 0.90 | SLC6A9 (0.60) | SLC6A9HPGDKMT2ACES1RAB9A | |
| SCHEMBL3059786 | 0.81 | SLC6A9 (0.63) | SLC6A9HPGDKMT2AMEN1GPR27 | |
| SCHEMBL3042565 | 0.80 | SLC6A9 (0.58) | SLC6A9HPGDKMT2AMEN1GPR27 | |
| SCHEMBL2854460 | 0.78 | SLC6A9 (0.60) | SLC6A9HPGDKMT2AMEN1 | |
| SCHEMBL7795359 | 0.74 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL4645715 | 0.72 | SLC6A9 (0.47) | SLC6A9HPGDKMT2ACES1RAB9A | |
| SCHEMBL3043124 | 0.71 | KDM4E (0.48) | SLC6A9HPGDRAB9ANPC1ALDH1A1 | |
| SCHEMBL4643554 | 0.71 | KDM4E (0.48) | SLC6A9HPGDRAB9ANPC1ALDH1A1 | |
| SCHEMBL4644071 | 0.71 | KDM4E (0.48) | SLC6A9HPGDRAB9ANPC1ALDH1A1 | |
| SCHEMBL4646402 | 0.70 | SLC6A9 (0.47) | SLC6A9HPGDKMT2ACES1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-1960360-A1 | AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME LTD. (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060484-A1 | AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | GRIA1, GLRA1, GRIN1 | SLC6A9 18/4885HPGD 2932/4885KMT2A 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.